Abstract
The term "immune privilege" was coined to describe weak immunogenicity (hypo-immunity) that manifests in some transplant settings. We extended this concept to encompass hypo-immunity that manifests at local sites of inflammation relevant to clinical diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a key metabolic process that promotes and sustains induced immune privilege, and discuss the implications for exploiting this knowledge to improve treatments for hypo-immune and hyper-immune syndromes using strategies to manipulate tryptophan metabolism.
Original language | English (US) |
---|---|
Article number | Article 109 |
Journal | Frontiers in immunology |
Volume | 3 |
Issue number | MAY |
DOIs | |
State | Published - 2012 |
Keywords
- IDO
- Immunity
- Inflammation
- Regulation
- Tolerance
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology